Dec'19 Actual | Dec'20 Actual | Dec'21 Actual | Dec'22 Actual | Dec'23 Actual | Dec'24 Estimate | Dec'25 Estimate | Dec'26 Estimate | Dec'27 Estimate | Dec'28 Estimate | Dec'29 Estimate | Dec'30 Estimate | Dec'31 Estimate | Dec'32 Estimate | Dec'33 Estimate | Dec'34 Terminal | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 82.6 209.4% | 148.8 80.2% | 271.9 82.8% | 526.9 93.8% | 872.0 65.5% | 1,460.1 67.4% | 2,044.2 40.0% | 2,347.6 14.8% | 2,740.5 16.7% | 2,834.0 3.4% | 2,924.1 3.2% | 3,010.1 2.9% | 3,091.5 2.7% | 3,167.9 2.5% | 3,238.7 2.2% | 3,303.5 2.0% |
% margin | (74.4) (90.1%) | (15.1) (10.2%) | (115.0) (42.3%) | (68.7) (13.0%) | (29.5) (3.4%) | (464.4) (31.8%) | (650.2) (31.8%) | (746.7) (31.8%) | (871.7) (31.8%) | (901.5) (31.8%) | (930.1) (31.8%) | (957.5) (31.8%) | (983.4) (31.8%) | (1,007.7) (31.8%) | (1,030.2) (31.8%) | (1,050.8) (31.8%) |
NOPAT % effective tax rate | (74.5) (90.2%) | (15.3) (10.3%) | (111.8) (41.1%) | (68.7) (13.0%) | (32.1) (3.7%) | (507.0) (34.7%) | (709.8) (34.7%) | (815.1) (34.7%) | (951.5) (34.7%) | (984.0) (34.7%) | (1,015.3) (34.7%) | (1,045.1) (34.7%) | (1,073.4) (34.7%) | (1,099.9) (34.7%) | (1,124.5) (34.7%) | (1,147.0) (34.7%) |
% of revenue | 0.3 0.3% | 1.1 0.7% | 4.1 1.5% | 7.5 1.4% | 9.5 1.1% | 19.5 1.3% | 27.3 1.3% | 31.4 1.3% | 36.6 1.3% | 37.9 1.3% | 39.1 1.3% | 40.2 1.3% | 41.3 1.3% | 42.3 1.3% | 43.3 1.3% | 44.1 1.3% |
% of revenue | (1.8) (2.2%) | (4.2) (2.8%) | (5.0) (1.8%) | (7.2) (1.4%) | (26.5) (3.0%) | (30.4) (2.1%) | (42.6) (2.1%) | (48.9) (2.1%) | (57.1) (2.1%) | (59.1) (2.1%) | (61.0) (2.1%) | (62.8) (2.1%) | (64.5) (2.1%) | (66.1) (2.1%) | (67.5) (2.1%) | (68.9) (2.1%) |
% of revenue | (9.9) (11.9%) | 4.2 2.8% | 3.5 1.3% | (14.2) (2.7%) | 20.8 2.4% | 4.7 0.3% | 6.6 0.3% | 7.5 0.3% | 8.8 0.3% | 9.1 0.3% | 9.4 0.3% | 9.7 0.3% | 9.9 0.3% | 10.2 0.3% | 10.4 0.3% | 10.6 0.3% |
Free Cash Flow to Firm (FCFF) % of revenue | (85.9) (104.0%) | (14.2) (9.6%) | (109.3) (40.2%) | (82.6) (15.7%) | (28.3) (3.2%) | (513.2) (35.1%) | (718.5) (35.1%) | (825.1) (35.1%) | (963.3) (35.1%) | (996.1) (35.1%) | (1,027.8) (35.1%) | (1,058.0) (35.1%) | (1,086.6) (35.1%) | (1,113.5) (35.1%) | (1,138.4) (35.1%) | (1,161.1) (35.1%) |
% of FCFF used in calculation | 100.0% | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||||||
Discount period | 0.50 | 1.50 | 2.50 | 3.50 | 4.50 | 5.50 | 6.50 | 7.50 | 8.50 | |||||||
Discount factor | 0.96 | 0.88 | 0.81 | 0.74 | 0.68 | 0.62 | 0.57 | 0.52 | 0.48 | |||||||
Discounted FCFF (DFCFF) |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of Mar 03, 2025, Hims & Hers Health, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by (100.0%) compared to its current price of around $40.7, using a WACC of 9.0% and growth rates of 2.0%.
As of Mar 03, 2025, Hims & Hers Health, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 9.0%.
As of Mar 03, 2025, Hims & Hers Health, Inc.'s Enterprise Value (EV) is approximately $0.0. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.